ArticleJournal of transplantation2009
A comprehensive review of immunosuppression used for liver transplantation.
Article in Journal of transplantation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.
- Pooled it
- Safety and Efficacy of Budesonide for Liver Transplant Immune Suppression: Results of a Pilot Phase 2a Trial.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2020Trial
- A Mechanism-Based Framework for Anti-Aging Strategies: From Metabolic Regulation to Senotherapy and Stem Cell-Based Interventions.Aging cell · 2026Review
- Early-Onset Bilateral Clear Cell Renal Cell Carcinoma in a Pediatric Renal Transplant Recipient: A Rare Case Report.Case reports in urology · 2026Article
- Incisional hernia repair following liver transplantation: A meta-analysis.World journal of transplantation · 2025Article
- Revolutionizing medicine: Exploring the breakthroughs in liver xenotransplantation.Liver research (Beijing, China) · 2025Review
- Immune Modulation Strategies in Gene Therapy: Overcoming Immune Barriers and Enhancing Efficacy.Current gene therapy · 2025Review
- Effects of combined cyclosporin and azithromycin treatment on human mononuclear cells under lipopolysaccharide challenge.Frontiers in oral health · 2025Article
- Design of PI3K-mTOR Dual Inhibitors for Ovarian Cancer: Are we on the Right Track?Current medicinal chemistry · 2025Review
- Review
- Tacrolimus Treatment for TAFRO Syndrome.Biomedicines · 2024Article
- Review
- Donor-Specific Blood Transfusion in Lung Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Molecular Glue Discovery: Current and Future Approaches.Journal of medicinal chemistry · 2023Review
- Acceptability of neural stem cell therapy for cerebral palsy: survey of the Australian cerebral palsy community.Stem cell research & therapy · 2023Article
- Development of a predictive nomogram for switching immunosuppressive drugs in pediatric liver transplant recipients.Frontiers in pediatrics · 2023Article
- Neutrophil depletion for early allogeneic islet survival in a methacrylic acid (MAA) copolymer-induced, vascularized subcutaneous space.Frontiers in transplantation · 2023Article
- The impact of COVID-19 on liver transplantation: challenges and perspectives.Therapeutic advances in gastroenterology · 2023Review
- Advances in Cardiac Tissue Engineering.Bioengineering (Basel, Switzerland) · 2022Review
- Perforin: An intriguing protein in allograft rejection immunology (Review).Experimental and therapeutic medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since liver transplantation was approved for the treatment of end stage liver disease, calcineurin inhibitors (CNI's) have played a critical role in the preservation of allograft function. Unfortunately, these medications cause a variety of Side effects such as diabetes, hypertension and nephrotoxicity which in turn result in significant morbidity and reduced quality of life. A variety of newer immunosuppressants have been evaluated over the last decade in an attempt to either substitute for CNI's or use with reduced dose CNI's while still preserving allograft function However, current data does not recommend complete cessation of CNI's due to unacceptably high rates of allograft rejection. As these medications have their own unique adverse effects, a careful assessment on their risks and benefits is essential, particularly when additive or synergistic effects with CNI's may occur. Furthermore, the impact of these newer medications on the risk of hepatitis C recurrence and progression remains to be elucidated. Controlled trials are urgently required to assist transplant physicians with choosing the optimum immunosuppressive regimen for their patients. This review will discuss commonly used immunosuppressants prescribed in liver transplantation, emerging therapties and where appropriate, the impact of these medications on the recurrence of hepatitis C after liver transplantation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.